Patents by Inventor Thomas Spector

Thomas Spector has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pharmaceutical compositions of 5-alkynyl uracil compounds
    Patent number: 6586440
    Abstract: This invention relates to pharmaceutical compositions of 5-alkynyluracil compounds in the form of tablets or capsules.
    Type: Grant
    Filed: April 23, 2001
    Date of Patent: July 1, 2003
    Assignee: SmithKline Beecham Corporation
    Inventors: Thomas Spector, David J. T. Porter, Saad George Rahim
  • Uracil reductase inactivators
    Publication number: 20020042392
    Abstract: Uracil reductase inactivators, notably a 5-substituted uracil or 5,6-dihydro-5-substituted uracil, potentiate 5-flourouracil and find use particularly in the treatment of cancer. The 5-substituent is selected from bromo, ido, cyano, halo-substituted C-1-4 alkyl, C2-6 alkenyl, 1-halo-C2-6 alkenyl and halo-substituted C2-6 alkynyl.
    Type: Application
    Filed: October 1, 2001
    Publication date: April 11, 2002
    Inventors: Thomas Spector, David J.T. Porter, Saad G. Rahim
  • Uracil reductase inactivatores
    Patent number: 6297223
    Abstract: Uracil reductase inactivators, notably a 5-substituted uracil or 5,6-dihydro-5-substituted uracil, potentiate 5-fluorouracil and find use particularly in the treatment of cancer. The 5-substituent is selected from bromo, iodo, cyano, halo-substituted C1-4 alkyl, C2-6 alkenyl, 1-halo-C2-6 alkenyl and halo-substituted C2-6 aklynyl.
    Type: Grant
    Filed: June 30, 2000
    Date of Patent: October 2, 2001
    Assignee: Glaxo Wellcome Inc.
    Inventors: Thomas Spector, David J. T. Porter, Saad G. Rahim
  • Enzyme inactivators
    Publication number: 20010025033
    Abstract: Use of uracil reductase inactivators such as 5-substituted uracil derivatives for example 5-ethynyluracil to reduce the toxicity of the anti-HIV nucleoside analogue zidovudine.
    Type: Application
    Filed: April 23, 2001
    Publication date: September 27, 2001
    Inventors: Thomas Spector, David J.T. Porter, Saad George Rahim
  • Uracil reductase inactivators
    Patent number: 6268374
    Abstract: The present invention relates to a group of 5-substituted uracil derivatives which are inactivators of uracil reductase and which are particularly useful in cancer chemotherapy, especially in combination with antimetabolite antineoplastic agents such as 5-fluorouracil.
    Type: Grant
    Filed: July 23, 1993
    Date of Patent: July 31, 2001
    Assignee: Glaxo Wellcome Inc.
    Inventors: Thomas Spector, David J. T. Porter, Saad G. Rahim
  • Pharmaceutical compositions of 5-alkynyl-dideoxyribouracil
    Patent number: 6221852
    Abstract: This application relates to pharmaceutical compositions of 5-alkynyl-dideoxyridbouracils which generates 5-alkynyluracils in vivo, which are inactivators of uracil reductase.
    Type: Grant
    Filed: April 3, 1997
    Date of Patent: April 24, 2001
    Assignee: Glaxo Wellcome Inc.
    Inventors: Thomas Spector, David J. T. Porter, Saad George Rahim
  • Pharmaceutical compositions of 5-alkynyl uracil compounds
    Patent number: 6177436
    Abstract: This invention relates to pharmaceutical compositions of 5-alkynuracil.
    Type: Grant
    Filed: April 3, 1997
    Date of Patent: January 23, 2001
    Assignee: Glaxo Wellcome Inc.
    Inventors: Thomas Spector, David J. T. Porter, Saad George Rahim
  • Uracil reductase inactivators
    Patent number: 5817664
    Abstract: The present invention relates to a group of 5-substituted uracil derivatives which are inactivators of uracil reductase and which are particularily useful in cancer chemotherapy, especially in combination with antimetabolite antineoplastic agents such as 5-fluorouracil (5-FU).
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: October 6, 1998
    Assignee: Glaxo Wellcome Inc.
    Inventors: Thomas Spector, David J. T. Porter, Saad G. Rahim
  • Pharmaceutical compositions of 5-substituted uracil compounds
    Patent number: 5643913
    Abstract: Pharmaceutical compositions containing 5-substituted uracil compounds are disclosed. The compositions are preferably in the form of a tablet or capsule.
    Type: Grant
    Filed: November 9, 1994
    Date of Patent: July 1, 1997
    Assignee: Glaxo Wellcome Inc.
    Inventors: Thomas Spector, David J. T. Porter, Saad George Rahim
  • Antiviral combinations and compounds therefor
    Patent number: 5393883
    Abstract: The present invention relates to novel ribonucleotide reductase inhibitors and new combinations comprising an antiviral compound, such as acyclovir, and a thiocarbonohydrazone ribonucleotide reductase inhibitor for the chemotherapeutic treatment of virus infections, especially viruses of the herpes group.
    Type: Grant
    Filed: February 7, 1992
    Date of Patent: February 28, 1995
    Assignee: Burroughs Wellcome Co.
    Inventors: Todd A. Blumenhopf, Thomas Spector, Devron R. Averett, Robert W. Morrison, Jr., Eric C. Bigham, Virgil L. Styles
  • Antiviral combinations and compounds therefor
    Patent number: 5175165
    Abstract: The present invention relates to novel ribonucleotide reductase inhibitors and new combinations comprising an antiviral compound, such as acyclovir, and a thiocarbonohydrazone ribonucleotide reductase inhibitor for the chemotherapeutic treatment of virus infections, espectially viruses of the herpes group.
    Type: Grant
    Filed: June 26, 1989
    Date of Patent: December 29, 1992
    Assignee: Burroughs Wellcome Co.
    Inventors: Todd A. Blumenkopf, Thomas Spector, Devron R. Averett, Robert W. Morrison, Jr., Eric C. Bigham, Virgil L. Styles
  • Antiviral combinations
    Patent number: 4758572
    Abstract: Synergistic combinations of nucleoside analogues, which are converted to viral DNA polymerase inhibitors through the action of at least one virus-induced enzyme, and thiosemicarbazone ribonucleotide reductase inhibitors are especially useful in combatting herpes virus infections.
    Type: Grant
    Filed: March 5, 1987
    Date of Patent: July 19, 1988
    Assignee: Burroughs Wellcome Co.
    Inventors: Thomas Spector, Devron R. Averett, Donald J. Nelson